ANIK Stock Overview
Anika Therapeutics, Inc., a joint preservation company, creates and delivers advancements in early intervention orthopedic care in the areas of osteoarthritis (OA) pain management, regenerative solutions, soft tissue repair, and bone preserving joint technologies in the United States, Europe, and internationally.
No risks detected for ANIK from our risk checks.
Anika Therapeutics, Inc. Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||US$31.47|
|52 Week High||US$41.19|
|52 Week Low||US$19.95|
|1 Month Change||4.80%|
|3 Month Change||38.82%|
|1 Year Change||-20.69%|
|3 Year Change||-44.84%|
|5 Year Change||-40.61%|
|Change since IPO||799.14%|
Recent News & Updates
Are Investors Undervaluing Anika Therapeutics, Inc. (NASDAQ:ANIK) By 48%?Jun 25
How Much Are Anika Therapeutics, Inc. (NASDAQ:ANIK) Insiders Taking Off The Table?Mar 16
Anika Therapeutics (NASDAQ:ANIK) Seems To Use Debt Quite SensiblyFeb 09
An Intrinsic Calculation For Anika Therapeutics, Inc. (NASDAQ:ANIK) Suggests It's 32% UndervaluedJan 13
If You Had Bought Anika Therapeutics' (NASDAQ:ANIK) Shares A Year Ago You Would Be Down 21%Dec 18
|ANIK||US Biotechs||US Market|
Return vs Industry: ANIK underperformed the US Biotechs industry which returned -10.2% over the past year.
Return vs Market: ANIK underperformed the US Market which returned -14.8% over the past year.
|ANIK Average Weekly Movement||6.9%|
|Biotechs Industry Average Movement||11.2%|
|Market Average Movement||7.4%|
|10% most volatile stocks in US Market||15.6%|
|10% least volatile stocks in US Market||3.3%|
Stable Share Price: ANIK is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 7% a week.
Volatility Over Time: ANIK's weekly volatility (7%) has been stable over the past year.
About the Company
Anika Therapeutics, Inc., a joint preservation company, creates and delivers advancements in early intervention orthopedic care in the areas of osteoarthritis (OA) pain management, regenerative solutions, soft tissue repair, and bone preserving joint technologies in the United States, Europe, and internationally. The company develops, manufactures, and commercializes products based on hyaluronic acid (HA) technology platform. Its OA pain management product family consists of Monovisc, Orthovisc, Cingal, and Hyvisc that are indicated to provide pain relief from osteoarthritis conditions; and joint preservation and restoration product family comprise a portfolio of approximately 150 bone preserving joint technology products, a line of sports medicine soft tissue repair solutions, and orthopedic regenerative solutions products.
Anika Therapeutics, Inc. Fundamentals Summary
|ANIK fundamental statistics|
Is ANIK overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|ANIK income statement (TTM)|
|Cost of Revenue||US$62.19m|
Last Reported Earnings
Sep 30, 2022
Next Earnings Date
|Earnings per share (EPS)||-1.08|
|Net Profit Margin||-10.33%|
How did ANIK perform over the long term?See historical performance and comparison